ChemRar Research and Development Institute, LLC Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2018
NCT04524975
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

ChemRar Research and Development Institute, LLC | "Research Center for Mental Health" Scientific Institution

Active Ingredients

Drugs in Phase 3 Trials (2)

cd-008-0045 (2 trials)

fabomotizole (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anxiety Disorders (Phase 3)

Disease (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2